Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Company Overview

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Key Stats

• Today's Range: $2.67 to $2.85
• 50-Day Range: $1.97 to $3.97
• 52-Week Range: $1.12 to $4.20
• Volume: 39,677 shs
• Average Volume: 371,544 shs
• Market Capitalization: $182.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Buy

Inhibikase Therapeutics Stock Analysis - MarketRank™

Inhibikase Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 801st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Inhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Inhibikase Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibikase Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibikase Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inhibikase Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IKT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibikase Therapeutics does not currently pay a dividend.

Dividend Growth

Inhibikase Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for IKT.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for IKT on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Inhibikase Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $198,650.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.59% of the stock of Inhibikase Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.81% of the stock of Inhibikase Therapeutics is held by institutions.

IKT Stock Analysis - Frequently Asked Questions

How have IKT shares performed this year?

Inhibikase Therapeutics' stock was trading at $3.25 at the beginning of 2025. Since then, IKT stock has decreased by 16.3% and is now trading at $2.72.
View the best growth stocks for 2025 here.

How were Inhibikase Therapeutics' earnings last quarter?

Inhibikase Therapeutics, Inc. (NYSE:IKT) released its earnings results on Monday, November, 15th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.24. The business earned $0.33 million during the quarter.

When did Inhibikase Therapeutics' stock split?

Shares of Inhibikase Therapeutics reverse split on Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did Inhibikase Therapeutics IPO?

Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) served as the underwriter for the IPO.

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inhibikase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 1/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:IKT
• CUSIP: N/A
• CIK: 1750149
• Web: www.inhibikase.com
• Phone: 678-392-3419
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.50
• High Stock Price Target: $8.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +139.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,030,000.00
• Net Margins: N/A
• Pretax Margin: -22,978.75%
• Return on Equity: -350.63%
• Return on Assets: -201.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $260,000.00
• Price / Sales: 702.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.78 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 67,190,000
• Free Float: 64,109,000
• Market Cap: $182.76 million
• Optionable: Not Optionable
• Beta: 1.11